A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

NCT06528093 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Primary endpoint not met

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: BI 765883
DRUG: gemcitabine
DRUG: nab-paclitaxel

Sponsor

Boehringer Ingelheim